Please feel free to contact us for a quote and further discussion with our scientists.
Datasheets
| Specifications | |
|---|---|
| Product Description | HG-7-85-01 is a type II kinase inhibitor targeting BCR-ABL that binds to the DFG-out conformation of the kinase domain. Its high affinity and specificity support its use as a recognition moiety in bifunctional chemical agents. |
| Molecular Formula | C31H31F3N6O2S |
| Molecular Weight (Da) | 608.7 |
| Chemical Name | 3-[2-(cyclopropanecarbonylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]-N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
| Chemical Structure |  |
| Purity | 0.99 |
| Size | 5 mg |
| Physical State | Powder |
| Storage | The power can be stored at 4 °C for 2 years or at -20 °C for 3 years. |
| Target Information | |
|---|---|
| Target Name | ABL1 |
| Alternative Names | ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL, c-ABL1, p150, v-abl |
| Introduction | ABL1 is a non-receptor tyrosine kinase containing an SH3 domain, an SH2 domain, and a C-terminal kinase domain. It localizes to both the cytoplasm and nucleus, where it regulates cell proliferation, cytoskeletal dynamics, and DNA damage responses. |
| Gene ID | 25 |
| UniProt ID | P00519 |
| Related Disease | Chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal stromal tumor |
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
